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INTRODUCTION
Pulmonary lymphovascular tumor embolism is a rare but 
important cause of rapidly progressing dyspnea in patients with 
cancer. A diagnosis of a pulmonary lymphovascular tumor 
embolism is rarely given before death, but the incidence of   
tumor involvement in the pulmonary lymphovascular struc-
ture is up to 26% in previous autopsy case reports [1,2]. Breast 
cancer is known as the most common primary source of         
microscopic pulmonary tumor emboli [3]. Previously reported 
cases of a pulmonary tumor embolism are mostly due to known 
primary malignancy, but in some cases, microscopic pulmo-
nary emboli in a patient presenting with progressive dyspnea 
is the very first presentation of cancer [4]. We report a patient 
with breast cancer relapsed with an extensive pulmonary lym-
phovascular tumor embolism during adjuvant chemotherapy, 
which was diagnosed and treated successfully.
CASE REPORT
A 38-year-old female patient was diagnosed with clinical 
Stage IIIC (cT2cN3M0) infiltrating ductal carcinoma of the 
left breast with left supraclavicular lymph nodes metastases. 
She was treated with neoadjuvant chemotherapy consisting of 
docetaxel and doxorubicin. After six cycles of chemotherapy, 
the supraclavicular lymph node was not palpable with a partial 
response of the breast cancer and the axillary nodes. She under-
went a curative resection for the breast cancer, and the final 
pathologic stage was ypStageIIIC (ypT2N3M0). Immunohis-
tochemistry showed negative staining for the estrogen receptor 
(ER), progesterone receptor (PR), and human epithelial growth 
factor receptor 2 (HER2). Histological and nuclear grades were 
III/III and 3/3, respectively, and extensive endolymphatic tumor 
emboli were present. Adjuvant chemotherapy with cyclophos-
phamide, methotrexate, and 5-fluorouracil (CMF) was com-
menced, but on her visit for the third cycle she complained of 
sudden-onset right chest pain and cough. Her chest X-ray was 
within normal limits (Figure 1A). Ten days later, she felt right 
inspiratory chest pain and was referred to the emergency         
department. She complained of dyspnea on exertion (DOE), 
cough, and a mild febrile sense, however, she denied the high 
fever, sputum, pitting edema, or orthopnea. Her initial vital 
signs were a heart rate of 97 beats per minute, respiratory rate 
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We describe a patient with breast cancer who relapsed with         
an extensive pulmonary lymphovascular tumor embolism. A 
38-year-old female, who previously received neoadjuvant che-
motherapy and curative resection of breast cancer, underwent 
adjuvant chemotherapy and was referred to the emergency room 
because of sudden-onset pleuritic chest pain lasting for 10 days. 
Despite a trial of empirical antibiotics, the chest pain and the     
extent of consolidative lung lesion on chest radiographs rapidly 
aggravated. We performed an open lung biopsy to confirm the 
etiology. The histopathological review revealed a hemorrhagic 
infarction caused by lymphovascular tumor emboli from a meta-
static breast carcinoma. Palliative first-line chemotherapy was 
administered, consisting of ixabepilone and capecitabine, and 
the lung lesion improved markedly. 
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of 20 per minute, blood pressure of 133/68 mmHg, body tem-
perature of 36.5°C, and oxygen saturation 97% on room air. 
Signs of respiratory distress were not definite. Fine crackles in 
the right upper lung field were present on chest auscultation 
but a pleural friction rub was not present. A chest X-ray dem-
onstrated patchy consolidation on the right upper lung field 
(Figure 1B) and computed tomography (CT) showed right 
upper lobe (RUL) patchy consolidation with ill-defined small 
ground glass opacities (GGO) in the RUL and right lower lobe 
(RLL) (Figure 2A, B, respectively). The differential diagnosis 
from the radiological study was pneumonia with a fungal eti-
ology but we could not rule out a bacterial etiology. The white 
blood cell count was 5,800/mm
3, and the segmented neutrophil 
portion was 76.4%. The C-reactive protein level was 0.86 mg/
dL (reference range, 0-0.5 mg/dL) and there was no evidence 
of pulmonary thromboembolism on chest CT.
We started empirical antibiotics with third generation ceph-
alosporin and macrolide under the impression of community 
acquired pneumonia, but the follow-up chest CT at 1 week 
showed an increased extent of RUL patchy consolidation (Fig-
ures 1C, 2C, D). Furthermore, subjective symptoms of dyspnea 
and pleuritic chest pain rapidly aggravated. No microorganisms 
were identified on the initial respiratory specimen culture. Find-
ings from chest X-rays and chest CT suggested fungal pneu-
monia, however, the patient had not experienced severe neu-
tropenia for several months, and there were no predisposing 
clinical factors favoring a diagnosis of fungal pneumonia. We 
considered the probability of lymphangitic metastatic carcino-
A C B
D E
Figure 1. (A) Chest PA at symptom presentation (10 days before emergency room visit). No remarkable findings are observed. (B) Chest PA at the 
emergency room. Patchy consolidative lesion on the right upper lobe (RUL) is shown (arrow). (C) After 1 week of empirical antibiotics for commu-
nity acquired pneumonia, RUL consolidation had not improved, and consolidation near the interlobar fissure and hilum increased in extent (arrow 
and arrowhead). (D) After the open lung biopsy and just before palliative chemotherapy, the RUL and the right lower lobe (RLL) consolidative lesion 
(arrow) and ground glass opacity further increased. (E) After 17 months of palliative chemotherapy, consolidative lesions in RUL and RLL decreased 
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ma or a fungal infection such as aspergillosis or mucormycosis. 
Therefore, we performed a video-assisted thoracoscopic lung 
biopsy for an accurate pathological diagnosis before administer-
ing antifungal agents. We thought it might be difficult to         
obtain a differential diagnosis using a percutaneous needle   
biopsy, because the nature of the lesion was infiltrative consol-
idation, not a mass. 
We performed a wedge resection of the RUL. The specimen 
was 6×3×3 cm, and a gross examination of the sections showed 
focal brownish discoloration of lung parenchyma without def-
inite evidence of necrosis, tumor, hemorrhage, or a calcified 
area. A microscopic examination showed metastatic carcino-
ma with extensive endolymphatic tumor emboli and hemor-
rhagic infarctions (Figures 3, 4). In contrast, Gram staining 
revealed no microorganisms and Gomori’s methenamine silver 
and periodic-acid Schiff stains revealed no fungal hyphae. The 
Mycobacterium tuberculosis-polymerase chain reaction result 
was also negative. 
We confirmed that the patient was not under infection, so 
we discontinued antimicrobial agents, enrolled the patient to 
the clinical trial and started first-line palliative chemotherapy 
consisting of ixabepilone (Ixempra
TM; Bristol-Myers Squibb, 
New York, USA) and capecitabine (Xeloda
®; Roche, Basel, 
Switzerland), as the disease had relapsed just 4 months after 
neoadjuvant docetaxel and doxorubicin and during adjuvant 
CMF chemotherapy (Figure 1D). This study was supported 
by a grant of the Korean Health Technology R&D Project, 
Ministry of Health & Welfare, Republic of Korea (A110448). 
After chemotherapy, the size of the consolidative lesion in the 
RUL and the extent of focal GGO in RUL and RLL decreased 
markedly. The pleuritic chest pain and DOE also improved. 
Currently, after 17 months, she is under palliative chemother-
Figure 2. (A, B) Chest computed tomography (CT) scan at the emergency room. Patchy consolidative mass-like lesion in the right upper lobe (RUL) 
(arrow) with focal ground glass opacity (GGO) (arrowhead). (C, D) After 1 week of empirical antibiotics for community acquired pneumonia, RUL con-
solidation and consolidation near the interlobar fissure and hilum increased in extent (arrows), and GGO of the RUL increased in extent (arrowhead).
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Figure 3. Microscopic appearance of the lung wedge resection specimen. 
Arrows show hemorrhagic infarction area. Arrowheads and asterisk   
indicate intravascular and endolymphatic tumor emboli, respectively. 
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apy and regular follow-up with partial response to the disease 
(Figure 1E).
DISCUSSION
A pulmonary tumor embolism is defined as tumor cells with-
in the pulmonary lymphovascular system that is not contiguous 
with metastatic foci [5]. The incidence of pulmonary tumor 
embolism varies widely among several studies, ranging from 
3% to 26% [2]. Symptoms of microscopic pulmonary tumor 
emboli include clinically unexplained subacute, progressive 
dyspnea, hypoxia, chest pain, cough, and respiratory alkalosis 
[2,5,6]. Right-sided heart failure and pulmonary hypertension 
are occasionally noted [2]. 
A pulmonary tumor embolism is rarely diagnosed before 
death, because a histological diagnosis is rarely made and hard 
to distinguish from thromboembolism; according to one study, 
only 6% of patients were correctly diagnosed antemortem [1]. 
A ventilation-perfusion scan with peripheral, symmetric per-
fusion defects can be used for diagnosis, but its clinical benefit 
is limited due to low sensitivity [2,3]. Therefore, a histological 
or cytological diagnosis by open lung biopsy, transbronchial 
lung biopsy, or microvascular cytology drawn from a wedged 
pulmonary artery catheter is necessary [1,2]. In the present 
case, obstruction of pulmonary lymphatics and vasculature 
resulted in a peripheral lung infarction, and these presented   
as consolidation and GGO on chest radiography and CT. In 
contrast, the true extent of tumor involvement in the resected 
lung specimen was tiny emboli confined to the lymphatics or 
microvessels, which is much smaller than shown in imaging 
studies. The presence of consolidation and GGO on imaging 
studies makes the diagnosis more difficult, because excluding 
an infection (such as bacterial, viral or fungal pneumonia) is 
difficult in a clinical situation. 
Pulmonary metastases with lymphovascular tumor emboli 
mimicking pneumonia were appropriately and timely diag-
nosed by wedge resection of the lung and improved after appro-
priate chemotherapy. The patient has currently survived more 
than 17 months after the event. Accurate and prompt diagno-
sis of a pulmonary tumor embolism and appropriate chemo-
therapy may provide an improved in the prognosis in these 
patients. 
Standard treatment for a pulmonary tumor embolism is not 
established, except for systemic chemotherapy. The response 
to therapy and the prognosis largely depend on the nature of 
the primary malignancies. Some reports have indicated a good 
response to chemo-sensitive tumors, but the outcome of the 
disease is generally poor [1,4,7,8]. In a recent report, unlike the 
cancer cells at the primary site, those in the pulmonary lym-
phovasculature were enriched with stem cell-like markers 
(OCT3/4
+, NANOG2
+, CD44
+/CD24
-/low, ALDH1
+), and these 
findings may explain the aggressiveness of the disease [8]. 
In patients with metastatic and locally advanced breast cancer 
resistant to both anthracyclines and taxanes, the superiority of 
capecitabine plus ixabepilone over capecitabine alone in terms 
of progression free survival and objective response has been 
demonstrated in a randomized phase III trial [9]. These clin- 
ical benefits were consistent across subgroups, including pa-
tients with ER-, PR-, and HER2-negative breast cancer, visceral 
metastases, more than two sites of metastatic disease, age ≥65 
years, or those with HER2–positive breast cancer, which are 
traditionally associated with a poor prognosis [9,10]. In the 
present case, the ER-, PR-, and HER2-negative breast cancer 
relapsed soon after neoadjuvant chemotherapy with docetaxel 
plus doxorubicin (within 4 months) and presented as extensive 
pulmonary tumor emboli, which are usually life-threatening 
without prompt and appropriate treatment. We promptly started 
active chemotherapy with capecitabine plus ixabepilone and 
have achieved survival of more than 17 months by this time. 
We recommend that if a patient with a known malignancy 
presents with a subacute course of progressive dyspnea with 
consolidation on imaging studies, the lung lesion does not 
A C B
Figure 4. (A) Arrowhead and asterisk indicate intravascular and endolymphatic tumor emboli, respectively. (B, C) Figures show magnified image of 
lymphovascular tumor emboli. 
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improve with empirical antimicrobial treatment, and if the 
clinical setting is not compatible with infection or thrombo-
embolism, the physician should consider the probability of 
pulmonary lymphovascular invasion with tumor emboli. Fur-
thermore, the physician should make an effort to obtain path-
ological confirmation and should start chemotherapy as soon 
as possible.  
CONFLICT OF INTEREST
The authors declare that they have no competing interests.
REFERENCES
1.	Goldhaber	SZ,	Dricker	E,	Buring	JE,	Eberlein	K,	Godleski	JJ,	Mayer	RJ,	
et	al.	Clinical	suspicion	of	autopsy-proven	thrombotic	and	tumor	pul-
monary	embolism	in	cancer	patients.	Am	Heart	J	1987;114:1432-5.
2.	Roberts	KE,	Hamele-Bena	D,	Saqi	A,	Stein	CA,	Cole	RP.	Pulmonary	
tumor	embolism:	a	review	of	the	literature.	Am	J	Med	2003;115:228-32.
3.	Sostman	HD,	Brown	M,	Toole	A,	Bobrow	S,	Gottschalk	A.	Perfusion	
scan	in	pulmonary	vascular/lymphangitic	carcinomatosis:	the	segmen-
tal	contour	pattern.	AJR	Am	J	Roentgenol	1981;137:1072-4.
4.	Gajdos	C,	Nierman	DM,	Moqtaderi	FF,	Brower	ST,	Lento	P,	Bleiweiss	IJ.	
Microscopic	pulmonary	tumor	emboli:	an	unusual	presentation	of	breast	
cancer.	Breast	J	2000;6:273-5.
5.	Bassiri	AG,	Haghighi	B,	Doyle	RL,	Berry	GJ,	Rizk	NW.	Pulmonary	tu-
mor	embolism.	Am	J	Respir	Crit	Care	Med	1997;155:2089-95.
6.	Aiyappan	V,	Alwail	A.	Pulmonary	tumor	thromboembolism:	a	case			
report	and	review	of	literature.	Ann	Thorac	Med	2007;2:169-70.
7.	Ejlertsen	B,	Jensen	MB,	Rank	F,	Rasmussen	BB,	Christiansen	P,	Kroman	
N,	et	al.	Population-based	study	of	peritumoral	lymphovascular	inva-
sion	and	outcome	among	patients	with	operable	breast	cancer.	J	Natl	
Cancer	Inst	2009;101:729-35.
8.	Kawasaki	H,	Ogura	H,	Arai	Y,	Baba	S,	Kosugi	I,	Tsutsui	Y,	et	al.	Aggres-
sive	progression	of	breast	cancer	with	microscopic	pulmonary	emboli	
possessing	a	stem	cell-like	phenotype	independent	of	its	origin.	Pathol	
Int	2010;60:228-34.
9.	Thomas	ES,	Gomez	HL,	Li	RK,	Chung	HC,	Fein	LE,	Chan	VF,	et	al.			
Ixabepilone	plus	capecitabine	for	metastatic	breast	cancer	progressing	
after	anthracycline	and	taxane	treatment.	J	Clin	Oncol	2007;25:5210-7.
10.	Perez	EA,	Patel	T,	Moreno-Aspitia	A.	Efficacy	of	ixabepilone	in	ER/PR/
HER2-negative	(triple-negative)	breast	cancer.	Breast	Cancer	Res	Treat	
2010;121:261-71.